MX2023000677A - Compuestos moduladores de receptor de estrogeno. - Google Patents
Compuestos moduladores de receptor de estrogeno.Info
- Publication number
- MX2023000677A MX2023000677A MX2023000677A MX2023000677A MX2023000677A MX 2023000677 A MX2023000677 A MX 2023000677A MX 2023000677 A MX2023000677 A MX 2023000677A MX 2023000677 A MX2023000677 A MX 2023000677A MX 2023000677 A MX2023000677 A MX 2023000677A
- Authority
- MX
- Mexico
- Prior art keywords
- estrogen receptor
- modulating compounds
- compounds
- receptor modulators
- estrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 239000002834 estrogen receptor modulator Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
- C07C43/253—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Abstract
En la presente se describen compuestos que son moduladores de receptor de estrógeno. También se describen composiciones farmacéuticas y medicamentos que incluyen los compuestos que se describen en la presente así como métodos de uso de estos moduladores de receptor de estrógeno, solos y en combinación con otros compuestos, para tratar enfermedades o condiciones que son medidas o que dependen de los receptores de estrógeno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862620441P | 2018-01-22 | 2018-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000677A true MX2023000677A (es) | 2023-02-13 |
Family
ID=65352172
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007731A MX2020007731A (es) | 2018-01-22 | 2019-01-22 | Compuestos moduladores de receptor de estrogeno. |
MX2023000677A MX2023000677A (es) | 2018-01-22 | 2020-07-21 | Compuestos moduladores de receptor de estrogeno. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007731A MX2020007731A (es) | 2018-01-22 | 2019-01-22 | Compuestos moduladores de receptor de estrogeno. |
Country Status (14)
Country | Link |
---|---|
US (2) | US11384068B2 (es) |
EP (1) | EP3743413A1 (es) |
JP (1) | JP7288450B2 (es) |
KR (1) | KR20200113229A (es) |
CN (1) | CN112105607A (es) |
AU (2) | AU2019210129B2 (es) |
BR (1) | BR112020014746A2 (es) |
CA (1) | CA3089298A1 (es) |
IL (2) | IL276152B2 (es) |
MA (1) | MA51670A (es) |
MX (2) | MX2020007731A (es) |
RU (1) | RU2020123999A (es) |
SG (1) | SG11202006942WA (es) |
WO (1) | WO2019144132A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022000553A2 (pt) * | 2019-07-22 | 2022-05-17 | Radius Pharmaceuticals Inc | Compostos moduladores do receptor de estrogênio |
JP7419575B2 (ja) | 2020-06-28 | 2024-01-22 | メッドシャイン ディスカバリー インコーポレイテッド | 縮合環インダゾール系化合物 |
TW202313558A (zh) * | 2021-07-08 | 2023-04-01 | 大陸商勤浩醫藥(蘇州)有限公司 | 一類苯并七元環類化合物及其應用 |
WO2024015506A1 (en) * | 2022-07-14 | 2024-01-18 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
CN117924262A (zh) * | 2022-10-14 | 2024-04-26 | 中国科学院上海药物研究所 | 二氢苯并噻喃类衍生物及其制备方法和用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916916A (en) | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
JP2001513501A (ja) * | 1997-08-07 | 2001-09-04 | イーライ・リリー・アンド・カンパニー | エストロゲン阻害活性を有する1−[4−(置換アルコキシ)ベンジル]ナフタレン化合物 |
DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
AU2002323098A1 (en) * | 2001-08-11 | 2003-03-03 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
ATE481397T1 (de) * | 2002-04-24 | 2010-10-15 | Merck Sharp & Dohme | Modulatoren des östrogenrezeptors |
BRPI0512395A (pt) * | 2004-06-22 | 2008-03-11 | Smithkline Beecham Corp | composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou a profilaxia de condições ou distúrbios associadas(os) com a modulação de receptor de estrogênio seletiva, e para o tratamento ou a profilaxia relacionado(a) com condições ou distúrbios |
JP2015500346A (ja) * | 2011-12-14 | 2015-01-05 | セラゴン ファーマシューティカルズ,インク. | エストロゲン受容体モジュレーターおよびその使用 |
RS57106B1 (sr) * | 2013-02-19 | 2018-06-29 | Novartis Ag | Derivati benzotiofena i njihove kompozicije kao selektivni degraderi estrogenskog receptora |
WO2014203132A1 (en) * | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
WO2016174551A1 (en) * | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
WO2017080966A1 (en) * | 2015-11-09 | 2017-05-18 | F. Hoffmann-La Roche Ag | Tetrahydronaphthalene estrogen receptor modulators and uses thereof |
-
2019
- 2019-01-22 WO PCT/US2019/014581 patent/WO2019144132A1/en active Application Filing
- 2019-01-22 CA CA3089298A patent/CA3089298A1/en active Pending
- 2019-01-22 SG SG11202006942WA patent/SG11202006942WA/en unknown
- 2019-01-22 CN CN201980021103.7A patent/CN112105607A/zh active Pending
- 2019-01-22 US US16/963,794 patent/US11384068B2/en active Active
- 2019-01-22 KR KR1020207023957A patent/KR20200113229A/ko not_active Application Discontinuation
- 2019-01-22 BR BR112020014746-0A patent/BR112020014746A2/pt unknown
- 2019-01-22 MX MX2020007731A patent/MX2020007731A/es unknown
- 2019-01-22 MA MA051670A patent/MA51670A/fr unknown
- 2019-01-22 RU RU2020123999A patent/RU2020123999A/ru unknown
- 2019-01-22 JP JP2020540428A patent/JP7288450B2/ja active Active
- 2019-01-22 EP EP19704152.8A patent/EP3743413A1/en active Pending
- 2019-01-22 AU AU2019210129A patent/AU2019210129B2/en active Active
- 2019-01-22 IL IL276152A patent/IL276152B2/en unknown
-
2020
- 2020-07-21 MX MX2023000677A patent/MX2023000677A/es unknown
-
2022
- 2022-05-31 US US17/828,832 patent/US20220332704A1/en active Pending
-
2023
- 2023-07-13 IL IL304460A patent/IL304460A/en unknown
- 2023-12-27 AU AU2023286007A patent/AU2023286007A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019144132A1 (en) | 2019-07-25 |
RU2020123999A (ru) | 2022-02-24 |
EP3743413A1 (en) | 2020-12-02 |
JP2021511343A (ja) | 2021-05-06 |
IL276152A (en) | 2020-09-30 |
IL276152B1 (en) | 2023-08-01 |
US11384068B2 (en) | 2022-07-12 |
US20200347032A1 (en) | 2020-11-05 |
MX2020007731A (es) | 2020-09-25 |
US20220332704A1 (en) | 2022-10-20 |
AU2023286007A1 (en) | 2024-01-25 |
SG11202006942WA (en) | 2020-08-28 |
IL276152B2 (en) | 2023-12-01 |
AU2019210129B2 (en) | 2023-09-28 |
KR20200113229A (ko) | 2020-10-06 |
CA3089298A1 (en) | 2019-07-25 |
BR112020014746A2 (pt) | 2020-12-08 |
IL304460A (en) | 2023-09-01 |
MA51670A (fr) | 2020-12-02 |
JP7288450B2 (ja) | 2023-06-07 |
AU2019210129A1 (en) | 2020-08-13 |
CN112105607A (zh) | 2020-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000677A (es) | Compuestos moduladores de receptor de estrogeno. | |
MX2015016171A (es) | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. | |
PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
PH12017501140A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
PH12015501737A1 (en) | Androgen receptor modulators and uses thereof | |
MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
MX2013002975A (es) | Moduladores de receptores de estrogenos y usos de los mismos. | |
PH12014501351A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
NZ737399A (en) | Ccr2 modulators | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
MX2018009752A (es) | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. | |
WO2011159769A3 (en) | Indane estrogen receptor modulators and uses thereof | |
DOP2010000234A (es) | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina | |
CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
EA033197B1 (ru) | Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b | |
MX2021015508A (es) | Carbamatos de piridina y su uso como moduladores del receptor glun2b. | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
MX2020000693A (es) | Compuestos de 1,8-naftiridinona, y usos de los mismos. | |
MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
MX2022011310A (es) | Azabiciclo y derivados de diazepina para tratar trastornos oculares. | |
MX2022000520A (es) | Compuestos moduladores del receptor de estrogeno. |